Reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is a membrane-anchored glycoprotein that negatively
regulates the activities of matrix metalloproteinases (MMPs) and inhibits tumor invasion, metastasis, and angiogenesis. RECK is
essential for normal development and is a key mediator of tissue remodeling and stabilization of tissue architechture. Downregulation of
RECK documented in a wide range of malignant neoplasms correlates with poor prognosis, and tumor metastasis. The RECK gene is a
common negative target for oncogenic signals that act on the Sp1-binding site of the RECK promoter. Both natural and synthetic agents
have been identified as upregulators of RECK. Several strategies have been proposed to enhance RECK expression including forced
expression of RECK, use of mimetics, recombinant peptides, microRNA antagonists, and gene therapy. Upregulation of RECK could be a
valuable therapeutic option to improve prognosis and block tumor progression. This review addresses the potential value of RECK as a
prognostic marker and as a molecular target for cancer therapy.
Keywords: Angiogenesis, Histone deacetylase, Invasion, Matrix metalloproteinases, RECK, Sp1 protein, Tissue inhibitor of matrix metalloproteinases, cytotrophoblasts, syncytiotrophoblasts, glycosylphosphatidylinositol.
Rights & PermissionsPrintExport
Published on: 22 August, 2012
Page: [718 - 725]